Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

City Centre Development

17 Jun 2010 07:00

RNS Number : 7721N
China Real Estate Opportunities PLC
17 June 2010
 



 

CHINA REAL ESTATE OPPORTUNITIES PLC

RECEIPT OF LETTERS FROM VENDORS OF CITY CENTER

 

China Real Estate Opportunities plc ("CREO" or the "Company"), is an AIM-listed company established to acquire investment and development properties in China.

 

On 24 May 2010 and 10 June 2010, CREO and CREO (Shanghai City Centre) Limited (which is a wholly-owned subsidiary of CREO) ("CSCCL") received letters (the "Letters") from the vendors of the City Center property (the "Vendors") requesting certain information, and alleging that certain conditions under the Share Purchase Agreement (as defined below and which was entered into in June 2007) may have occurred or may be likely to occur. If substantiated, the allegation may potentially result in a future payment by CREO of an amount of up to approximately GBP14 million to the Vendors (as defined below).

 

CSCCL and CREO have obtained advice and opinions from both Hong Kong and Peoples Republic of China counsel indicating that the request for information has no basis and any alleged claim for payment as set forth in the Letters have no merit. Accordingly, CSCCL and CREO intend to defend their position vigorously. CSCCL and CREO are of the view that the Letters have been sent at an opportunistic time in light of the impending listing by introduction of Treasury China Trust on Singapore Exchange Securities Trading Limited (the "SGX-ST").

 

CREO will make further announcements as and when there are material developments in the above matters.

 

The City Center Share Purchase Agreement

On 1 June 2007, CSCCL and CREO entered into a share purchase agreement in respect of the acquisition by CSCCL of Brightime Limited and State Properties Limited (the "Share Purchase Agreement") from the Vendors. Brightime Limited and State Properties Limited, through their wholly owned subsidiary Shanghai Hua Tian Property Development Co., Ltd. ("Hua Tian"), own the City Center property in Shanghai.

 

Contact:

 

CREO

Ray Horney, Chairman

Tel: 07797 314 1596

 

Sarah Moriarty, Investor Relations

Tel: +353 1 6189455

 

Matrix Corporate CapitalPaul Fincham Tel +44 (0)20 3206 7000

 

Davy

Des Carville

Tel: +353 1 679 6363

 

Citigate Dewe Rogerson

Tom Baldock

Tel: + 44 (0) 20 7638 9571

 

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUBOVRRNANARR
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.